Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

Istvan Bitter, Martin R K Dossenbach, Shlomo Brook, Peter D. Feldman, Stephen Metcalfe, Carlo A. Gagiano, János Füredi, György Bartko, Zoltan Janka, Csaba M. Banki, Gabor Kovacs, Alan Breier

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities. This has prompted the search for therapeutic alternatives for treatment-resistant schizophrenia. The objective of this study was to compare the efficacy and safety of olanzapine versus clozapine in schizophrenic patients who failed to respond adequately to antipsychotic medication or who experienced intolerable adverse effects associated with the medication. This 18-week, randomized, double-blind, parallel study compared treatment with either olanzapine (5-25 mg/day, n=75) or clozapine (100-500 mg/day, n=72) in patients with schizophrenia who were nonresponsive to, or intolerant of, standard acceptable antipsychotic therapy. At the 18-week endpoint, no statistically significant differences were found between olanzapine and clozapine in any efficacy measure used: Positive and Negative Syndrome Scale (PANSS) total, positive, negative, or general psychopathology or Clinical Global Impression severity (CGI-S). Response rates based on the criteria of Kane et al. [Arch. Gen. Psychiatry 45 (1988) 789] were also not significantly different between olanzapine-treated (57.9%) and clozapine-treated patients (60.8%). There were no significant differences in measurements of extrapyramidal symptoms or electrocardiography, and no clinically and statistically significant changes were seen in vital signs or laboratory measures in either group. Both treatments were well tolerated. Olanzapine demonstrated similar efficacy to clozapine in patients who had failed previous treatment because of lack of efficacy (treatment resistance) or intolerable side effects (treatment intolerance). Olanzapine therefore presents a safe alternative in the treatment of refractory schizophrenia.

Original languageEnglish (US)
Pages (from-to)173-180
Number of pages8
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume28
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

olanzapine
Clozapine
Schizophrenia
Therapeutics
Antipsychotic Agents
Safety
Vital Signs
Psychopathology
Double-Blind Method

Keywords

  • Clozapine
  • Drug resistance
  • Drug tolerance
  • Olanzapine
  • Schizophrenia
  • Treatment resistance

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. / Bitter, Istvan; Dossenbach, Martin R K; Brook, Shlomo; Feldman, Peter D.; Metcalfe, Stephen; Gagiano, Carlo A.; Füredi, János; Bartko, György; Janka, Zoltan; Banki, Csaba M.; Kovacs, Gabor; Breier, Alan.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, No. 1, 01.2004, p. 173-180.

Research output: Contribution to journalArticle

Bitter, I, Dossenbach, MRK, Brook, S, Feldman, PD, Metcalfe, S, Gagiano, CA, Füredi, J, Bartko, G, Janka, Z, Banki, CM, Kovacs, G & Breier, A 2004, 'Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 28, no. 1, pp. 173-180. https://doi.org/10.1016/j.pnpbp.2003.09.033
Bitter, Istvan ; Dossenbach, Martin R K ; Brook, Shlomo ; Feldman, Peter D. ; Metcalfe, Stephen ; Gagiano, Carlo A. ; Füredi, János ; Bartko, György ; Janka, Zoltan ; Banki, Csaba M. ; Kovacs, Gabor ; Breier, Alan. / Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2004 ; Vol. 28, No. 1. pp. 173-180.
@article{c99e008bc3334046bfd280a70e7048a5,
title = "Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia",
abstract = "Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities. This has prompted the search for therapeutic alternatives for treatment-resistant schizophrenia. The objective of this study was to compare the efficacy and safety of olanzapine versus clozapine in schizophrenic patients who failed to respond adequately to antipsychotic medication or who experienced intolerable adverse effects associated with the medication. This 18-week, randomized, double-blind, parallel study compared treatment with either olanzapine (5-25 mg/day, n=75) or clozapine (100-500 mg/day, n=72) in patients with schizophrenia who were nonresponsive to, or intolerant of, standard acceptable antipsychotic therapy. At the 18-week endpoint, no statistically significant differences were found between olanzapine and clozapine in any efficacy measure used: Positive and Negative Syndrome Scale (PANSS) total, positive, negative, or general psychopathology or Clinical Global Impression severity (CGI-S). Response rates based on the criteria of Kane et al. [Arch. Gen. Psychiatry 45 (1988) 789] were also not significantly different between olanzapine-treated (57.9{\%}) and clozapine-treated patients (60.8{\%}). There were no significant differences in measurements of extrapyramidal symptoms or electrocardiography, and no clinically and statistically significant changes were seen in vital signs or laboratory measures in either group. Both treatments were well tolerated. Olanzapine demonstrated similar efficacy to clozapine in patients who had failed previous treatment because of lack of efficacy (treatment resistance) or intolerable side effects (treatment intolerance). Olanzapine therefore presents a safe alternative in the treatment of refractory schizophrenia.",
keywords = "Clozapine, Drug resistance, Drug tolerance, Olanzapine, Schizophrenia, Treatment resistance",
author = "Istvan Bitter and Dossenbach, {Martin R K} and Shlomo Brook and Feldman, {Peter D.} and Stephen Metcalfe and Gagiano, {Carlo A.} and J{\'a}nos F{\"u}redi and Gy{\"o}rgy Bartko and Zoltan Janka and Banki, {Csaba M.} and Gabor Kovacs and Alan Breier",
year = "2004",
month = "1",
doi = "10.1016/j.pnpbp.2003.09.033",
language = "English (US)",
volume = "28",
pages = "173--180",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

AU - Bitter, Istvan

AU - Dossenbach, Martin R K

AU - Brook, Shlomo

AU - Feldman, Peter D.

AU - Metcalfe, Stephen

AU - Gagiano, Carlo A.

AU - Füredi, János

AU - Bartko, György

AU - Janka, Zoltan

AU - Banki, Csaba M.

AU - Kovacs, Gabor

AU - Breier, Alan

PY - 2004/1

Y1 - 2004/1

N2 - Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities. This has prompted the search for therapeutic alternatives for treatment-resistant schizophrenia. The objective of this study was to compare the efficacy and safety of olanzapine versus clozapine in schizophrenic patients who failed to respond adequately to antipsychotic medication or who experienced intolerable adverse effects associated with the medication. This 18-week, randomized, double-blind, parallel study compared treatment with either olanzapine (5-25 mg/day, n=75) or clozapine (100-500 mg/day, n=72) in patients with schizophrenia who were nonresponsive to, or intolerant of, standard acceptable antipsychotic therapy. At the 18-week endpoint, no statistically significant differences were found between olanzapine and clozapine in any efficacy measure used: Positive and Negative Syndrome Scale (PANSS) total, positive, negative, or general psychopathology or Clinical Global Impression severity (CGI-S). Response rates based on the criteria of Kane et al. [Arch. Gen. Psychiatry 45 (1988) 789] were also not significantly different between olanzapine-treated (57.9%) and clozapine-treated patients (60.8%). There were no significant differences in measurements of extrapyramidal symptoms or electrocardiography, and no clinically and statistically significant changes were seen in vital signs or laboratory measures in either group. Both treatments were well tolerated. Olanzapine demonstrated similar efficacy to clozapine in patients who had failed previous treatment because of lack of efficacy (treatment resistance) or intolerable side effects (treatment intolerance). Olanzapine therefore presents a safe alternative in the treatment of refractory schizophrenia.

AB - Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities. This has prompted the search for therapeutic alternatives for treatment-resistant schizophrenia. The objective of this study was to compare the efficacy and safety of olanzapine versus clozapine in schizophrenic patients who failed to respond adequately to antipsychotic medication or who experienced intolerable adverse effects associated with the medication. This 18-week, randomized, double-blind, parallel study compared treatment with either olanzapine (5-25 mg/day, n=75) or clozapine (100-500 mg/day, n=72) in patients with schizophrenia who were nonresponsive to, or intolerant of, standard acceptable antipsychotic therapy. At the 18-week endpoint, no statistically significant differences were found between olanzapine and clozapine in any efficacy measure used: Positive and Negative Syndrome Scale (PANSS) total, positive, negative, or general psychopathology or Clinical Global Impression severity (CGI-S). Response rates based on the criteria of Kane et al. [Arch. Gen. Psychiatry 45 (1988) 789] were also not significantly different between olanzapine-treated (57.9%) and clozapine-treated patients (60.8%). There were no significant differences in measurements of extrapyramidal symptoms or electrocardiography, and no clinically and statistically significant changes were seen in vital signs or laboratory measures in either group. Both treatments were well tolerated. Olanzapine demonstrated similar efficacy to clozapine in patients who had failed previous treatment because of lack of efficacy (treatment resistance) or intolerable side effects (treatment intolerance). Olanzapine therefore presents a safe alternative in the treatment of refractory schizophrenia.

KW - Clozapine

KW - Drug resistance

KW - Drug tolerance

KW - Olanzapine

KW - Schizophrenia

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=10744231049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744231049&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2003.09.033

DO - 10.1016/j.pnpbp.2003.09.033

M3 - Article

VL - 28

SP - 173

EP - 180

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -